T. Rowe Price Associates’s Acumen Pharmaceuticals ABOS Stock Holding History

T. Rowe Price Associates’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$106K	Buy	+39,327	New	+$97.1K	﹤0.01%	3135
2025 Q2	–	Sell	-13,616	Closed	-$15K	–	3058
2025 Q1	$15K	Hold	13,616	–	–	﹤0.01%	3016
2024 Q4	$24K	Sell	13,616 -836,003	-98%	-$2.01M	﹤0.01%	2985
2024 Q3	$2.11M	Sell	849,619 -196,745	-19%	-$534K	﹤0.01%	1611
2024 Q2	$2.53M	Sell	1,046,364 -51,912	-5%	-$165K	﹤0.01%	1453
2024 Q1	$4.45M	Buy	+1,098,276	New	+$4.14M	﹤0.01%	1249

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

T. Rowe Price Associates's ABOS Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Acumen Pharmaceuticals (ABOS) in Q2 2026: 39,327 shares worth $106K. The stake represents ﹤0.01% of the portfolio and ranks #3135 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in ABOS as recently as Q1 2025.

T. Rowe Price Associates first reported a position in ABOS in Q1 2024 and has held it in 6 quarters since. The position peaked at $4.45M in Q1 2024. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

T. Rowe Price Associates held 39,327 shares of Acumen Pharmaceuticals worth $106K as of Q2 2026.
Acumen Pharmaceuticals was a new T. Rowe Price Associates position in Q2 2026.
Acumen Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3135 holding.
T. Rowe Price Associates first reported a position in Acumen Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
T. Rowe Price Associates's Acumen Pharmaceuticals position peaked at $4.45M in Q1 2024.
96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.